Antigen delivery by virus-like particles for immunotherapeutic vaccination

Farah Al-Barwani; Braeden Donaldson; Simon J. Pelham; Sarah L. Young; Vernon K. Ward

doi:10.4155/tde.14.74

Antigen delivery by virus-like particles for immunotherapeutic vaccination

Farah Al-Barwani, Braeden Donaldson, Simon J. Pelham, Sarah L. Young, Vernon K. Ward^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

30 Citations (Scopus)

Abstract

Virus-like particles (VLPs) are an effective means of establishing both prophylactic and therapeutic immunity against their source virus or heterologous antigens. The particulate nature and repetitive structure of VLPs makes them ideal for stimulating potent immune responses. Epitopes delivered by VLPs can be presented on MHC-II for stimulation of a humoral immune response, or cross-presented onto MHC-I leading to cell-mediated immunity. VLPs as particulate subunit vaccine carriers are showing promise in preclinical and clinical trials for the treatment of many conditions including cancer, autoimmunity, allergies and addiction. Supporting the delivery of almost any form of antigenic material, VLPs are ideal candidate vectors for development of future vaccines.

Original language	English
Pages (from-to)	1223-1240
Number of pages	18
Journal	Therapeutic Delivery
Volume	5
Issue number	11
DOIs	https://doi.org/10.4155/tde.14.74
Publication status	Published - Nov 1 2014
Externally published	Yes

ASJC Scopus subject areas

Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4155/tde.14.74

Cite this

@article{a8fa7f9bd8bf49e5821355eb604911ef,

title = "Antigen delivery by virus-like particles for immunotherapeutic vaccination",

abstract = "Virus-like particles (VLPs) are an effective means of establishing both prophylactic and therapeutic immunity against their source virus or heterologous antigens. The particulate nature and repetitive structure of VLPs makes them ideal for stimulating potent immune responses. Epitopes delivered by VLPs can be presented on MHC-II for stimulation of a humoral immune response, or cross-presented onto MHC-I leading to cell-mediated immunity. VLPs as particulate subunit vaccine carriers are showing promise in preclinical and clinical trials for the treatment of many conditions including cancer, autoimmunity, allergies and addiction. Supporting the delivery of almost any form of antigenic material, VLPs are ideal candidate vectors for development of future vaccines.",

author = "Farah Al-Barwani and Braeden Donaldson and Pelham, {Simon J.} and Young, {Sarah L.} and Ward, {Vernon K.}",

note = "Publisher Copyright: {\textcopyright} 2014 Future Science Ltd.",

year = "2014",

month = nov,

day = "1",

doi = "10.4155/tde.14.74",

language = "English",

volume = "5",

pages = "1223--1240",

journal = "Therapeutic Delivery",

issn = "2041-5990",

publisher = "Future Science",

number = "11",

}

TY - JOUR

T1 - Antigen delivery by virus-like particles for immunotherapeutic vaccination

AU - Al-Barwani, Farah

AU - Donaldson, Braeden

AU - Pelham, Simon J.

AU - Young, Sarah L.

AU - Ward, Vernon K.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Virus-like particles (VLPs) are an effective means of establishing both prophylactic and therapeutic immunity against their source virus or heterologous antigens. The particulate nature and repetitive structure of VLPs makes them ideal for stimulating potent immune responses. Epitopes delivered by VLPs can be presented on MHC-II for stimulation of a humoral immune response, or cross-presented onto MHC-I leading to cell-mediated immunity. VLPs as particulate subunit vaccine carriers are showing promise in preclinical and clinical trials for the treatment of many conditions including cancer, autoimmunity, allergies and addiction. Supporting the delivery of almost any form of antigenic material, VLPs are ideal candidate vectors for development of future vaccines.

AB - Virus-like particles (VLPs) are an effective means of establishing both prophylactic and therapeutic immunity against their source virus or heterologous antigens. The particulate nature and repetitive structure of VLPs makes them ideal for stimulating potent immune responses. Epitopes delivered by VLPs can be presented on MHC-II for stimulation of a humoral immune response, or cross-presented onto MHC-I leading to cell-mediated immunity. VLPs as particulate subunit vaccine carriers are showing promise in preclinical and clinical trials for the treatment of many conditions including cancer, autoimmunity, allergies and addiction. Supporting the delivery of almost any form of antigenic material, VLPs are ideal candidate vectors for development of future vaccines.

UR - http://www.scopus.com/inward/record.url?scp=84917671708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84917671708&partnerID=8YFLogxK

U2 - 10.4155/tde.14.74

DO - 10.4155/tde.14.74

M3 - Review article

C2 - 25491672

AN - SCOPUS:84917671708

SN - 2041-5990

VL - 5

SP - 1223

EP - 1240

JO - Therapeutic Delivery

JF - Therapeutic Delivery

IS - 11

ER -

Antigen delivery by virus-like particles for immunotherapeutic vaccination

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this